NBCL develops and provides an ultra-sensitive point-of-care platform utilizing the NBCL CONNECT Analyzer for rapid diagnostic testing. This system delivers high-sensitivity assay results, such as ioPTH, in just five minutes using minimal sample preparation. The platform enables healthcare professionals to obtain immediate, actionable laboratory data at the point of care.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for parathyroid hormone (PTH) testing often require sending samples to a central lab, resulting in turnaround times that can delay treatment decisions. Existing point-of-care PTH assays may lack the sensitivity or specificity needed for accurate diagnosis and monitoring of parathyroid disorders.
Solution
NBCL has developed the NBCL CONNECT Analyzer, a point-of-care system that delivers intact PTH assay results from whole blood samples in five minutes. The analyzer is designed for ease of use, requiring minimal training and enabling rapid diagnostic testing in various healthcare settings. The system aims to provide clinicians with timely information to guide treatment decisions related to calcium homeostasis and parathyroid function. In addition to PTH assays, NBCL offers custom assay development services for other biomarkers on its platform and other diagnostic platforms.
Target Audience
The primary target audience includes hospitals, clinics, and other healthcare providers needing rapid and accurate PTH measurements at the point of care, as well as research institutions seeking custom assay development services.
Features
- Rapid intact PTH assay results from whole blood in 5 minutes
- Point-of-care system designed for use in diverse healthcare settings
- Simple three-step operation: scan blood sample, scan reagent cartridge, and test
- Minimal training required for operation
- Custom assay development services for various biomarkers
- Potential for future acute care assays (hs-cTnI, BNP, D-Dimer)